Back to News
Market Impact: 0.15
AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
AEON Biopharma's aggregate one-year analyst price target was raised 16.39% to $1.81 per share from $1.56 as of September 11, 2026. The revision indicates a modestly improved analyst outlook, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
AEON0.35
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October